Indiana to Assume Some NRC Nuclear Safety Duties
Published Date: 5/29/2026
Notice
Summary
The Nuclear Regulatory Commission (NRC) is teaming up with Indiana to let the state take charge of some nuclear safety rules. This means Indiana will handle certain nuclear materials oversight, helping protect public health while keeping things running smoothly. People have until June 15, 2026, to share their thoughts before the agreement moves forward—no big costs or delays expected!
Analyzed Economic Effects
4 provisions identified: 0 benefits, 2 costs, 2 mixed.
213 NRC Licenses Move to Indiana
The NRC would discontinue its authority and transfer regulatory oversight of 213 licenses to the State of Indiana. After the effective date, those NRC licenses would continue in effect as State of Indiana licenses until they expire or are replaced; the NRC will publish the final Agreement and effective date after Commission approval.
State Staffing and Inspection Frequency
Indiana will staff the Radioactive Materials Control Program with the equivalent of four full-time professional and technical staff and has adopted an inspection schedule that is as frequent as, or more frequent than, the NRC schedule. The NRC staff found the Indiana program adequate and compatible with NRC requirements.
Certain Activities Stay With NRC
The Agreement explicitly preserves NRC authority over specific areas including regulation of construction/operation/decommissioning of production or utilization facilities, byproduct material defined in Section 11e.(2), export/import of materials, ocean disposal, certain sealed source evaluations/registrations, and some land disposal activities. Entities engaged in those activities would remain under NRC regulation, not the State of Indiana.
Future NRC Rule Changes Will Require State Updates
The notice states that when the NRC finalizes rules during implementation of Executive Order 14300 (issued May 23, 2025), Agreement States, including Indiana, will need to update their regulations as necessary to maintain compatibility with the NRC program within a specified timeframe. This will require future state rulemaking to stay aligned with NRC changes.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-08015 — Generic Environmental Impact Statement for Licensing of New Nuclear Reactors
The Nuclear Regulatory Commission just updated the rules for checking the environmental impact of new nuclear reactors. This makes it easier and faster to review many reactors by using a common set of environmental factors, while still looking closely at unique site details. The new rules kick in on May 26, 2026, helping companies save time and money when applying to build new reactors.
2026-06048 — Risk-Informed, Technology-Inclusive Regulatory Framework for Advanced Reactors
The Nuclear Regulatory Commission is updating its rules to make it easier and faster to approve new types of nuclear reactors, not just the old light-water ones. This change helps companies building advanced reactors by using smarter, risk-based rules that fit new technology. The new rules start on April 29, 2026, and could save time and money for the nuclear industry and the public.
2026-04823 — Fee Schedules; Fee Recovery for Fiscal Year 2026
The Nuclear Regulatory Commission (NRC) is updating its fees for licenses, inspections, and special projects for fiscal year 2026. These changes aim to cover nearly all NRC costs and set fixed fee limits to boost efficiency and fairness. If you’re involved with the NRC, get ready for new fees by September 30, 2026, and don’t miss the April 13 deadline to share your thoughts!
2025-14147 — Fee Schedules; Fee Recovery for Fiscal Year 2025
The U.S. Nuclear Regulatory Commission fixed a typo in their fee schedule for 2025. This update affects companies and government agencies that pay licensing and inspection fees, making sure the right amounts are charged. The corrected fees kick in soon, so everyone can plan their budgets without surprises!
2025-11544 — Fee Schedules; Fee Recovery for Fiscal Year 2025
The U.S. Nuclear Regulatory Commission is updating its fees for licenses, inspections, and special projects starting in fiscal year 2025. These changes make sure the NRC recovers nearly all its costs, while giving a break with lower hourly rates for advanced nuclear reactor applicants. If you’re involved with nuclear licensing or inspections, get ready for new fees and some savings on cutting-edge tech!
2025-02779 — Fee Schedules; Fee Recovery for Fiscal Year 2025
The U.S. Nuclear Regulatory Commission is updating its fees for licenses, inspections, and special projects starting in fiscal year 2025. These changes make sure the NRC covers almost all its costs, while giving a discount to advanced nuclear reactor applicants. If you’re involved with nuclear licensing or inspections, get ready for new fees and some savings on cutting-edge tech!
Previous / Next Documents
Previous: 2026-10701 — Notice of an Amended Order Under Sections 362 and 365 of the Public Health Service Act Suspending Introduction of Certain Persons From Countries Where a Communicable Disease Exists
Starting May 22, 2026, the CDC is pausing entry for certain travelers from countries with contagious disease outbreaks for 30 days. This new rule now includes lawful permanent residents, who were previously exempt. If you’re affected or interested, you have until June 22 to share your thoughts—no money changes, just health safety first!
Next: 2026-10703 — Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Guidance for Industry; Availability
The FDA just released final guidance to help drug companies prove their generic drugs work just like the original ones by using bioequivalence studies. This affects anyone submitting or updating abbreviated new drug applications (ANDAs) and aims to make the approval process clearer and smoother. Companies should review these new rules now to avoid delays and extra costs when getting their generics to market.